Latest Headlines
- 3PBIOVIAN Awarded At The CDMO Leadership Awards 2025 In The Cell & Gene Therapy International Category 5/14/2025
-
3PBIOVIAN Unveils Two Groundbreaking Technology Platforms For AAV And pDNA Manufacturing
5/14/2025
3PBIOVIAN, a trusted CDMO partner in biopharmaceutical manufacturing proudly announced today the launch of AAVion® Platform, a fully integrated adeno-associated virus (AAV) manufacturing solution, designed to accelerate gene therapy development.
-
Andelyn Biosciences Applies The AAV CuratorĀ® Platform To Deliver Novel Gene Therapy For An Ultra-Rare NEDAMSS Disease Patient 14-Months After Diagnosis
5/12/2025
Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has successfully manufactured a novel viral vector gene therapy with its AAV Curator® Platform to treat a baby with the ultra-rare disease Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS).
-
VintaBio Unveils New Data Showcasing Scalable AAV Perfusion Manufacturing Platform With High Full Capsid Yield At 2025 ASGCT Annual Meeting
5/8/2025
VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present transformative data on its proprietary VintaProcess™, an advanced intensified adherent viral vector manufacturing platform.
-
Minaris Advanced Therapies Launches As The Leading Global Partner Dedicated To Cell Therapy Development, Manufacturing, And Testing
5/7/2025
Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi Advanced Therapies have been combined to form Minaris Advanced Therapies, a global cell therapy CDMO and testing partner.
-
3P innovation Launches Next-Generation DPI Filling Technology For Novel Inhalation Therapeutics
5/1/2025
Patent expiry of original product enables 3P innovation to design enhanced equivalent DPI filling system for developers and CMOs.
-
AST Celebrates 60 Years Of Excellence In Innovation And Looks To The Future Of Drug Product Manufacturing
5/1/2025
AST marked the launch of its 60th anniversary year at INTERPHEX 2025, using the prestigious industry event as a springboard to highlight six decades of innovation. Building on the momentum of being named “Best in Show” at INTERPHEX 2024, AST entered its 60th anniversary receiving another reputable honor: the INTERPHEX Efficiency Champion award. This back-to-back recognition highlights not only AST’s legacy of innovation but also its forward-looking approach to advancing excellence across the industry.
-
RoosterBio Announces Collaboration With Thermo Fisher Scientific To Advance Cell And Exosome Therapy Manufacturing
4/29/2025
RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science.
-
Cytiva And Asimov Collaborate On Next Generation Cell Line Design And Process Development
4/29/2025
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva, a global life sciences leader, to provide customers with an integrated offering for optimized biologics production.
-
Avance Clinical To Showcase Asia-Pacific Clinical Trial Expertise At BIO Korea 2025
4/15/2025
Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech research services, will attend BIO Korea 2025 to meet with biotechs and share clinical trial capabilities across the region including Australia, New Zealand, South Korea, Taiwan, North America and beyond.